Research institutions at 27 sites across North America have been selected as part of the new Cancer Immunotherapy Trials Network (CITN). The CITN will conduct multicenter research on agents that boost patients’ own immune systems to fight their cancer. By coordinating the efforts of academia, industry, and philanthropic foundations, the CITN is charged with accelerating the development of promising agents that have already been discovered but are not currently used to treat patients with cancer.
An open competition was held for institutions to apply for member site status in the CITN, and immunotherapy experts evaluated candidates on the experience, participation, and collaboration of the investigators and their institutions in immunotherapy trials and their ability to provide laboratory expertise in tumor immunology to support the trials.
The member institutions and their principal investigators are:
Baylor Research Institute – Dr. Karolina Palucka
Case Western Reserve University – Dr. Pierre Triozzi
Dana-Farber Cancer Institute – Dr. Stephen Hodi
Dartmouth-Hitchcock Norris Cotton Cancer Center – Dr. Marc Ernstoff
Duke University Medical Center – Dr. Kim Lyerly
Emory University – Dr. Edmund Waller
Fred Hutchinson Cancer Research Center – Dr. John A. Thompson
H. Lee Moffitt Cancer Center – Dr. Scott J. Antonia
Memorial Sloan-Kettering Cancer Center – Dr. Jedd D. Wolchok
New York University Cancer Institute – Dr. Nina Bhardwaj
Ohio State University – Dr. William E. Carson
Providence Cancer Center – Dr. Walter J. Urba
Roswell Park Cancer Institute – Dr. Kunle Odunsi
Rush University Cancer Center – Dr. Howard Kaufman
Stanford University – Dr. Ronald Levy
University of California, San Diego – Dr. Thomas J. Kipps
University of California, San Francisco – Dr. Lawrence Fong
University of Chicago – Dr. Thomas Gajewski
University of Miami – Dr. Joseph D. Rosenblatt
University of Minnesota – Dr. Jeffrey S. Miller
University of Pennsylvania – Dr. Carl June
University of Pittsburgh – Dr. Robert L. Ferris
University of Texas M. D. Anderson Cancer Center – Dr. Laurence J. N. Cooper
University of Toronto, Ontario Cancer Institute – Dr. Pamela Ohashi
University of Virginia – Dr. Craig Slingluff
University of Wisconsin – Dr. Paul M. Sondel
Yale University – Dr. Mario Sznol
In September 2010, funding was awarded to the Fred Hutchinson Cancer Research Center in Seattle to serve as the network’s Central Operations and Statistical Center (COSC). Directed by principal investigator Dr. Martin A. Cheever and co-investigators Drs. Mary L. Disis and Kim Margolin, the COSC will provide overall leadership and infrastructure for the CITN. The network will be managed in concert with the NIH/NIAID-funded HIV Vaccine Trials Network (HVTN), also based at the Fred Hutchinson Cancer Research Center. The NCI’s Cancer Trials Support Unit will operate the data coordination effort for CITN.
An initial meeting of CITN investigators is scheduled for May 9–10 in Bethesda, MD, to discuss the operations of the CITN and to introduce the first concepts to be studied by this new cancer immunotherapy program.
NCI Cancer Bulletin for April 5, 2011 - National Cancer Institute
No hay comentarios:
Publicar un comentario